- Home
- CRNX
as 12-17-2024 4:00pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 5.2B | IPO Year: | 2018 |
| Target Price: | $74.40 | AVG Volume (30 days): | 594.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $33.67 - $62.53 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,038,999 | Revenue Growth: | -78.00% |
| Revenue Growth (this year): | -58.93% | Revenue Growth (next year): | 195.21% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | CRNX | President & CEO | Dec 2 '24 | Sell | $57.57 | 10,000 | $575,700.00 | 100,000 | |
| Knight Jeff E. | CRNX | Chief Operating Officer | Nov 22 '24 | Sell | $56.52 | 501 | $28,316.52 | 51,653 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Oct 3 '24 | Sell | $54.63 | 14,375 | $785,306.25 | 28,507 | |
| Wilson Marc | CRNX | CFO | Sep 26 '24 | Sell | $51.11 | 25,000 | $1,277,750.00 | 111,092 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
GlobeNewswire
7 days ago
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
9 days ago
Crinetics Pharmaceuticals Says US FDA Accepts NDA for Paltusotine to Treat Acromegaly
GlobeNewswire
9 days ago
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
GlobeNewswire
a month ago
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
GlobeNewswire
a month ago
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Simply Wall St.
a month ago
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)
GuruFocus.com
a month ago
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.